Alliance for Clinical Trials in Oncology
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Alliance for Clinical Trials in Oncology sits in the top decile of US sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count).
Alliance for Clinical Trials in Oncology: 446 sponsored US clinical trials, 29 recruiting.
Alliance for Clinical Trials in Oncology sponsors 446 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 346 completed. 142 of these trials are in Phase 3-4 (later-stage) and 235 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 19 trials.
Top-decile sponsor footprint
Alliance for Clinical Trials in Oncology ranks in the top decile of sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
346 of 377 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
446 total, page 6 of 9
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
NCT00068666
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
NCT00074035
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00070486
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
NCT00072475
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
NCT00077233
Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00072527
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
NCT00072046
Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer
NCT00060320
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
NCT00054457
(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy
NCT00075842
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
NCT00068328
Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer
NCT00063960
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
NCT00060333
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
NCT00053885
Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583
NCT00898833
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
NCT00049127
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
NCT00059852
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
NCT00058331
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
NCT00054418
Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
NCT00059826
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
NCT00045591
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
NCT00053196
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
NCT00052910
EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
NCT00046891
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00052845
Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
NCT00043069
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
NCT00040885
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
NCT00042965
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
NCT00052481
Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
NCT00040859
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
NCT00049010
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00041054
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
NCT00039130
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
NCT00017121
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00032032
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
NCT00041119
Standard Chest Tube Compared With a Small Catheter in Treating Malignant Pleural Effusion in Patients With Cancer
NCT00042770
Genetic Study of Young Patients With Colorectal Cancer
NCT00044967
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy
NCT00048971
Medroxyprogesterone Compared With Venlafaxine in Treating Hot Flashes in Women
NCT00030914
Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease
NCT00031720
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
NCT00031980
Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT00033553
Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking
NCT00033592
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
NCT00033397
Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy
NCT00027963
Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer
NCT00032006
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00032019
Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00022139
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
NCT00022087
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 209 |
| Phase 3 | 142 |
What is open in the Alliance for Clinical Trials in Oncology pipeline
29 recruiting of 446 indexed (7% open); 346 completed (78%).
Phase mix: 142 late (III/IV) vs 235 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alliance for Clinical Trials in Oncology: open-pipeline peers nationwide
Peers matched on 446 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 446 trials (± recruiting share)
- Medical College of Wisconsin · 447 trials · 21% recruiting
- University of Virginia · 449 trials · 22% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- Novo Nordisk A/S · 431 trials · 8% recruiting
Sponsors near 7% open enrollment (± trial volume)
- National Institutes of Health Clinical Center (CC) · 7% recruiting · 338 trials
- Insmed Incorporated · 6% recruiting · 31 trials
- NICHD Neonatal Research Network · 7% recruiting · 61 trials
- Hennepin Healthcare Research Institute · 6% recruiting · 63 trials
Related
What to do with this Alliance for Clinical Trials in Oncology page
446 registered trials is a research-attention snapshot, not an endorsement of Alliance for Clinical Trials in Oncology or any single study.
- 29 of Alliance for Clinical Trials in Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Alliance for Clinical Trials in Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alliance for Clinical Trials in Oncology pipeline card: 446 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.